文献速递临床试验与 GCP基础与转化研究

实验性注意偏差修正后接受承诺疗法治疗复发性抑郁:随机对照试验研究方案

Acceptance and Commitment Therapy preceded by an experimental Attention Bias Modification procedure in recurrent depression: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-03-27

本研究将120名近期完成注意偏差修正(ABM)或对照的复发性抑郁缓解期患者纳入8周团体接纳承诺疗法(ACT),在Phase 1结束后即刻、1个月、2个月、6个月及1年评估残留症状,探讨ABM能否增强ACT疗效及治疗过程与结局的关系。

要点

  • ABM后接团体ACT可能增强对抑郁残留症状的改善。
  • 评估时点为Phase 1结束后即刻、1、2、6个月及1年。
  • 将分析治疗过程与结局的关系。

核心结论

  • 旨在探讨先进行ABM能否增强团体ACT对复发性抑郁残留症状的疗效,并评估治疗过程与结局的关系。

研究设计与样本

  • 邀请120名来自Sørlandet站点、刚完成Phase 1随机多站点临床试验的个体参与。
  • Phase 1样本共220名有至少两次重性抑郁发作史且当前处于缓解期或不满足重性抑郁标准者。
  • Phase 1中ABM组n=60,无偏差修正对照组n=60。
  • 本阶段所有参与者接受为期8周的团体ACT干预。

关键数值与推荐

  • 评估时点:Phase 1结束后即刻、1个月、2个月、6个月及1年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This project studies the effect of group-based Acceptance and Commitment Therapy (ACT) following Attention Bias Modification (ABM) on residual symptoms in recurrent depression. ACT is a cognitive-behavioral intervention combining acceptance and mindfulness processes with commitment and behavior-change processes. ACT enjoys modest empirical support in treating depression and has also shown promising results in secondary prevention of depression. The experimental cognitive bias modification (ABM) procedure has been shown to reduce surrogate markers of depression vulnerability in patients in remission from depression. The aim of the current project is to investigate if the effect of group-based ACT on reducing residual depressive symptoms can be enhanced by preceding it with ABM. Also, assessment of the relationship between conceptually relevant therapeutic processes and outcome will be investigated. METHODS/DESIGN: An invitation to participate in this project was extended to 120 individuals within a larger sample who had just completed a separate randomized, multisite, clinical trial (referred to hereafter as Phase 1) in which they received either ABM (n = 60) or a control condition without bias modification (n = 60). This larger Phase-1 sample consisted of 220 persons with a history of at least two episodes of major depression who were currently in remission or not fulfilling the criteria of major depression. After its inclusion, Phase-1 participants from the Sørlandet site (n = 120) were also recruited for this study in which they received an 8-week group-based ACT intervention. Measures will be taken immediately after Phase 1, 1 month, 2 months, 6 months, and 1 year after the conclusion of Phase 1. DISCUSSION: This study sequentially combines acceptable, nondrug interventions from neuropsychology and cognitive-behavioral psychology in treating residual symptoms in depression. The results will provide information about the effectiveness of treatment and on mechanisms and processes of change that may be valuable in understanding and further developing ABM and ACT, combined and alone. TRIAL REGISTRATION: ClinicalTrials.gov, Identifier: NCT02648165 . Registered on 6 January 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Østergaard T, Lundgren T, Zettle R, et al. Acceptance and Commitment Therapy preceded by an experimental Attention Bias Modification procedure in recurrent depression: study protocol for a randomized controlled trial. Trials. 2018. PMID: 29587807. doi:10.1186/s13063-018-2515-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。